25% of large US employers, those with 500 or more employees, now offer or plan to offer enhanced or standalone menopause benefits in 2026, up from just 4% in 2023, according to PwC. That growth reflects a business case that has become harder to ignore. Women who seek medical care for menopause symptoms earn 10% less four years later, largely because many reduce hours or leave the workforce entirely. Menopause-related productivity loss costs US employers approximately $1.8 billion annually, according to Mayo Clinic estimates.
Employee expectation has moved even faster than employer adoption. 69% of women feel employers have a responsibility to offer menopause support, and more than 60% say menopause benefits would make them feel more supported at work, according to WebMD Health Services’ 2025 Menopause in the Workplace Study. The distance between what employees expect and what most employers currently offer is where vendors and benefits leaders now need to focus.
What Employers Should Be Evaluating
The menopause benefits vendor landscape has expanded quickly, and clinical rigor varies significantly across it. Employers should look for care models built around the guidelines set by the North American Menopause Society, since alignment with an established clinical standard is a meaningful signal that a vendor is offering evidence-based hormone therapy and symptom management grounded in real clinical practice.
Insurance coverage claims deserve real scrutiny beyond the marketing page. A vendor’s in-network status with an employer’s health plan does not automatically mean smooth reimbursement for employees, and complaints about billing confusion and unexpected self-pay charges have surfaced even among some of the most well-funded platforms in this category. Employers should ask vendors directly how claims are processed and what employees actually experience at the point of care.
Cost predictability matters as much as clinical quality. Unpredictable utilization is one of the biggest budget risks employers face when adding a new benefit category in 2026, according to Benepass, and vendors who can provide clear utilization data and cost modeling based on comparable employer populations make the budgeting conversation dramatically easier for a benefits team building next year’s plan.
What Separates the Vendors Closing Deals
The strongest positioning in this category treats menopause as one part of a broader midlife health picture. Perimenopause symptoms often overlap with thyroid function, mood, sleep, and metabolic health, and vendors who can address that full picture are positioned more strongly than those offering hormone therapy alone.
Retention data is the strongest lever available in a sales conversation, and vendors who can translate the productivity and retention statistics into a defensible case for a specific employer’s workforce demographics have an advantage over vendors relying on general awareness messaging. A benefits leader evaluating multiple vendors wants to see the retention argument made concretely, tied to the actual age distribution and turnover cost of their own workforce.
Transparency about insurance and reimbursement experience has become a genuine differentiator. Vendors who proactively address how claims processing works, and who can point to a track record of accurate coverage information reaching employees, are solving a trust problem that is costing competitors real pipeline.
Where This Leaves the Market
Menopause benefits have moved from a niche offering to a mainstream expectation faster than most employers anticipated, and the vendors and benefits leaders who treat clinical rigor, cost predictability, and genuine transparency as non-negotiable are the ones building programs that actually get used.
This is the fourth installment in a Brivio Health Insights series on growth in women’s health.
